Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

PRIMO 2023 | Unanswered questions in screening for prostate cancer

Ravi Madan • 3 Mar 2023
PRIMO 2023
Genitourinary Cancer Prostate Cancer

Ravi Madan, MD, National Cancer Institute, Bethesda, MD, provides an overview of remaining issues relating to prostate cancer screening. Underdiagnosis in patients may result in an increase of metastatic prostate cancer. There is consequently a need for novel biomarkers in addition to PSA screening. This interview took place at the Practical Recommendations in Immuno and Molecular Oncology (PRIMO) 2023 Congress in Honolulu, HI.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Ravi Madan

3:50
Advancing prostate cancer diagnosis with PSMA PET: opportunities and cautions
Ravi Madan • 12 Jun 2023
5:21
Prospective monitoring of patients with recurrent prostate cancer using serial PSMA imaging
Ravi Madan • 12 Jun 2023
2:17
ASCO 2023: highlights in prostate cancer
Ravi Madan • 12 Jun 2023
3:06
Treatment intensification in metastatic castration-sensitive prostate cancer
Ravi Madan • 12 Jun 2023

Related Videos

4:12
PETRA: saruparib in solid tumors with BRCA1/2, PALB2 or RAD51C/D mutations
Timothy Yap • 7 Apr 2024
0:45
SYNC-T combination immunotherapy in mCRPC
George Prendergast • 8 Apr 2024
0:40
PSMA PET findings in 225AC-J591-treated patients with mCRPC
Andres Ricaurte-Fajardo • 9 Apr 2024
0:45
Should radioligand therapies be used in earlier settings in prostate cancer?
Andres Ricaurte-Fajardo • 9 Apr 2024
The content of VJOncology is intended for healthcare professionals